Table 2.
Factors associated with overall survival in 33 patients treated with nivolumab monotherapy.
| Characteristics | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | ||
| Age | <60 vs. ≥60 | 2.065 | 0.734–5.807 | 0.169 | |||
| Sex | Male vs. Female | 0.457 | 0.151–1.384 | 0.166 | |||
| Tumor size, cm | <5 vs. ≥5 | 0.181 | 0.056–0.586 | 0.004 | 0.269 | 0.080-0.906 | 0.034 |
| PVTT | Yes vs. No | 1.868 | 0.695–5.020 | 0.215 | |||
| AFP, ng/mL | <1000 vs. ≥1000 | 0.980 | 0.382–2.511 | 0.966 | |||
| Child–Pugh score | 5 vs. 6 | 0.380 | 0.150–0.966 | 0.042 | |||
| ALBI grade | Grade 1 vs. 2 | 0.236 | 0.083–0.675 | 0.007 | 0.312 | 0.103-0.949 | 0.040 |
AFP, alpha fetoprotein; AFP, alpha fetoprotein; ALBI grade, albumin-bilirubin grade; CI, confidence interval; HR, hazard ratio. Significant factors in multivariate analysis are in bold characters.